covid19_progression Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Biol. Pharm. Bull., 34, 1257-1263 (2011). 利用者は研究成果の公表にあたって謝辞の表明を必要とする。利用者は提供承諾書を用いて、事前に西塚誠博士(nishizuka@hirosaki-u.ac.jp)の承諾を得る。営利機関の利用者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合医は、寄託者との別途協議を行う。 C(3〜6か月) C57BL/6コンジェニック系統。C57BL/6Jに13世代戻し交配を行っている。交配によりY染色体はB6置換済み。 C (3-6 months) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Biol Pharm Bull. 2011 34(8):1257-63. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from Dr.Makoto Nishizuka (nishizuka@hirosaki-u.ac.jp) using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 名古屋市立大学大学院薬学研究科 今川正良先生/西塚 誠先生と大阪大学遺伝情報実験センター 伊川正人先生 (2006年) true RBRC05143 Fad158 (Lrrc8c) knockout mice. Homozygous mutnat mice do not show body weight gain and insulin resistance by a high-fat diet. Developed by Graduate School of Pharmaceutical Sciences, Nagoya City University and Genome Information Research Center, Osaka University in 2006. A neomycin selection cassette was inserted into the exon 4 of the Fad158 gene. C57BL/6J background. Heterozygote x Wild-type B6-Fad158 KO#7 B6-Fad158 KO#7 D3 [129S2/SvPas] 今川 正良 mouse Pgk1 promoter, E. coli neomycin resistance gene, mouse Pgk1 polyA, mouse Fad158 genomic DNA <a href='https://brc.riken.jp/mus/pcr05143'>Genotyping protocol -PCR-</a> Fad158 (Lrrc8c) knockout mice. Homozygous mutant mice do not show body weight gain and insulin resistance by a high-fat diet. Diabetes and Obesity Research B6.129S2-Fad158<tm1Maim>/7Maim B6.129S2-Fad158<tm1Maim>/7Maim Developed by Graduate School of Pharmaceutical Sciences, Nagoya City University and Genome Information Research Center, Osaka University in 2006. A neomycin selection cassette was inserted into the exon 4 of the Fad158 gene. C57BL/6J background. Fad158は脂肪細胞分化初期に一過性に発現が増加する因子として単離された新規遺伝子である。Fad158は小胞体に局在し、脂肪細胞分化を促進する因子であることがわかっている。Fad158のKOマウスはインスリン感受性の亢進が観察されており、糖尿病研究に非常に有用である。 Masayoshi IMAGAWA